Metabolic reprogramming in cancer is not only a core hallmark but also exposes treatment vulnerabilities.Several key processes required for tumor initiation and progression—continuous self-renewal,survival,and prolif...Metabolic reprogramming in cancer is not only a core hallmark but also exposes treatment vulnerabilities.Several key processes required for tumor initiation and progression—continuous self-renewal,survival,and proliferation—are known to be under metabolic control^(1).Therapeutic opportunities arise from dysregulated metabolism and metabolic crosstalk,as tumor cells become heavily dependent on specific metabolic pathways such as glucose,amino acid,and fatty acid metabolism,as well as nucleotide synthesis^(2).However,many anti-metabolite drugs,including glycolysis inhibitors,have not been successfully applied in clinical settings due to their low specificity and undesirable side effects.展开更多
文摘Metabolic reprogramming in cancer is not only a core hallmark but also exposes treatment vulnerabilities.Several key processes required for tumor initiation and progression—continuous self-renewal,survival,and proliferation—are known to be under metabolic control^(1).Therapeutic opportunities arise from dysregulated metabolism and metabolic crosstalk,as tumor cells become heavily dependent on specific metabolic pathways such as glucose,amino acid,and fatty acid metabolism,as well as nucleotide synthesis^(2).However,many anti-metabolite drugs,including glycolysis inhibitors,have not been successfully applied in clinical settings due to their low specificity and undesirable side effects.
